TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17192164
Drug: Sedating antihistamines
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedating antihistamines
Study: 17192164
Drug: Melatonin (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (herbal preparation)
Study: 17192164
Drug: Valerian (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian (herbal preparation)
Study: 17192164
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (nonpharmacologic option)
Study: 17192164
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (nonpharmacologic option)
Study: 12404219
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg 3 times daily) for 5 days
Study: 12404219
Drug: Aspirin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (5 days)
Study: 31499384
Drug: Active supportive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supportive care (ASC) + oral erlotinib
Study: 25913109
Drug: Δ(9)-THC at
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Δ(9)-THC at .015 mg/kg
Study: 25913109
Drug: Δ(9)-THC at
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Δ(9)-THC at .03 mg/kg
Study: 25913109
Drug: Δ(9)-THC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)-THC (both doses)
Study: 20610478
Drug: RPE cell‐suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPE cell‐suspension transplantation (group 2)
Study: 19283647
Drug: Other anticonvulsants
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anticonvulsants
Study: 15061348
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment experts
Study: 11210393
Drug: Eniporide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniporide (2.5 to 100 mg, administered intravenously)
Study: 7800183
Drug: Ventilatory setting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ventilatory setting with constant tidal volume (VC = 8 ml.kg‐1) and varying respiratory frequencies (f = 10, 12, and 14 breaths.min‐1)
Study: 7800183
Drug: Constant ventilation
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant ventilation (112 ml.kg‐1) with modified VC and f
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (30 mg ml-1, 25 μl) as a 0.75 mg single dose (Cohort 1)
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (0.75 mg twice daily for 14 days, Cohort 2)
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (0.75 mg thrice daily for 14 days, Cohort 3)
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (1.5 mg thrice daily unilaterally for 3 days, then bilaterally for up to 14 days, Cohort 4)
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (0.75 mg)
Study: 29315699
Drug: Regorafenib eye
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib eye drops (up to 30 mg ml-1 tid)
Study: 12577163
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Study: 12577163
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesia (PCA) with tramadol (20 mg/ml) and dipyrone (200 mg/ml)
Study: 12577163
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of tramadol and dipyrone
Study: 10858338
Drug: Nelfinavir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir at a dose of 500 or 750 mg three times a day
Study: 10858338
Drug: Nelfinavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir with concomitant fluconazole therapy
Study: 10858338
Drug: Nelfinavir without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir without fluconazole therapy
Study: 19473225
Drug: Glutamate supplementation
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate supplementation (500 mg three times daily)
Study: 17899046
Drug: BAY 63‐9044
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐9044 (0.25 mg, 0.5 mg, 1.2 mg, 2.5 mg, 5.0 mg)
Study: 17899046
Drug: BAY 63‐9044
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐9044 (0.5 mg)
Study: 17899046
Drug: BAY 63‐9044
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐9044 (1.2 mg)
Study: 17899046
Drug: BAY 63‐9044
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 63‐9044 (highest two doses)
Study: 8877724
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide 300 mg/m2 on day -3
Study: 8877724
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 50 mg daily from days -14 to -3
Study: 3972647
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (Dextran, Diazepam, and Vitamins)
Study: 27356642
Drug: Automated intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated intermittent boluses of 10 ml of 0.2% ropivacaine every 60 mins for 48 hours
Study: 27356642
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 10 ml/h of 0.2% ropivacaine for 48 hours
Study: 22850709
Drug: Latex membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latex membrane implant
Study: 22850709
Drug: Sylastic® membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sylastic® membrane implant
Study: 22850709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no transitory implant
Study: 12913186
Drug: KW-6002 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-6002 (80 mg)
Study: 1614072
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (enalapril 5 mg + felodipine 5 mg)
Study: 1614072
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg added to enalapril 5 mg
Study: 1614072
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg added to felodipine 5 mg
Study: 6599697
Drug: Nifedipine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 3 X 10‐20 mg/day
Study: 6599697
Drug: Nifedipine +
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine + chlorthalidone, 25 to 50 mg/day
Study: 31250880
Drug: Palbociclib at
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years
Study: 27277115
Drug: Chlorophyll c2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophyll c2 (0.7 mg daily for 12 weeks)
Study: 23684697
Drug: No oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No oxytocin augmentation
Study: 20420787
Drug: Fesoterodine 28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 28 mg
Study: 18611271
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) administered twice at eight-week intervals during the transmission season.
Study: 18611271
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the first 16 weeks of follow-up.
Study: 18611271
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the subsequent transmission season.
Study: 18611271
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo response to treatment with SP.
Study: 12124559
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with additional antioxidants (Allopurinol, vitamin E and C, N‐acetylcysteine, and mannitol)
Study: 1769413
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg, twice daily for 10 days
Study: 1769413
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg, twice daily for 10 days
Study: 1769413
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg, twice daily for 10 days
Study: 25575502
Drug: Randomized drug
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized drug treatment in mild-to-moderate hypertension
Study: 19321506
Drug: Intranasal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal diamorphine plus intravenous morphine
Study: 19321506
Drug: Intranasal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal diamorphine plus oral morphine
Study: 17125605
Drug: Telbivudine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 200 mg
Study: 17125605
Drug: Telbivudine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 400 mg
Study: 17125605
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg (single dose)
Study: 17125605
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg (multiple doses for 8 days)
Study: 17125605
Drug: Telbivudine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 800 mg
Study: 11738277
Drug: Daily 400-microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 400-microg folic acid supplement plus natural diet
Study: 9286744
Drug: Candy bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candy bar (C1: 280 kcal, 36 g CHO)
Study: 9286744
Drug: Fat-free fig
Normalized name: Fig
DrugBank: Fig (DB10633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free fig bars (C2: 200 kcal, 44 g CHO)
Study: 3520795
Drug: 10-15 mg
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mg prednisone daily
Study: 26517404
Drug: Electronic reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic reading (tablet and computer display at 100% and 330% zoom levels)
Study: 20656516
Drug: Cerebrolysin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 20 mL administered once daily for 24 weeks
Study: 19473603
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m.
Study: 19473603
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 p.m.
Study: 19473603
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m. or p.m.
Study: 15259895
Drug: Lamivudine alone
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine alone (150 mg/day for 96 weeks)
Study: 852337
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Isoniazid (5 to 6 mg/kg), Ethambutol (25 mg/kg), Rifampin (10 mg/kg) daily for 6 months
Study: 852337
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Same therapy as group 1 for 6 months, then Isoniazid (5 mg/kg three days per week) for an additional 6 months
Study: 16619360
Drug: STA-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA-1 (80 g/kg/day, administered twice daily for 6 months)
Study: 16619360
Drug: Placebo (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (80 g/kg/day, administered twice daily for 6 months)
Study: 12791625
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (234 mg cocoa flavanols and procyanidins/d)
Study: 12791625
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (<= 6 mg cocoa flavanols and procyanidins/d)
Study: 9153458
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 100, 200, or 400 mg
Study: 9153458
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) titrated up to 400 mg
Study: 7957540
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dexfenfluramine taken with 250 ml water
Study: 7957540
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluoxetine pretreatment at -8 h
Study: 7957540
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine daily for 14 days
Study: 7957540
Drug: Dexfenfluramine alone
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine alone 14 days after cessation of 14 days of fluoxetine treatment
Study: 3588052
Drug: Cisapride (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.3 mg/kg initial dose, followed by 0.15 mg/kg every 4 hr for 12 hr)
Study: 18940401
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise (6-month program with weekly training sessions)
Study: 12912818
Drug: Methionine-loading test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine-loading test (100 mg/kg body weight, administered orally)
Study: 10825325
Drug: 0.08% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% bupivacaine plus 2 microg/mL fentanyl (BF)
Study: 10825325
Drug: 0.08% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% ropivacaine plus 2 microg/mL fentanyl (RF)
Study: 27072546
Drug: High G
Normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High G tolerance group (H group)
Study: 27072546
Drug: Low G
Normalized name: Yellow Ginger Root
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low G tolerance group (L group)
Study: 25351474
Drug: MEM 1414
Normalized name: MEM 1414
DrugBank: MEM 1414 (DB05888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEM 1414 (600 mg, twice daily orally for 7 days)
Study: 17906853
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) - intravenous bolus of 100 mg preceding a continuous infusion of 10 mg/h (n = 15)
Study: 16425053
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment in combination with cognitive behavioural therapy
Study: 1511475
Drug: Fruits and
Normalized name: Aminobenzoic Acid/Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Choline Bitartrate/Copper/Cyanocobalamin/Folic Acid/Inositol/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phosphorus/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin E/Zinc 5 MG-180 MG-300 MCG-120 MG-30 MCG-5 MG-2 MG-18 MCG-800 MCG-5 MG-150 MCG-18 MG-100 MG-2 MG-20 MG-30 MG-15 MG-2 MG-5.1 MG-4.5 MG-2250 MCG-7 MG-5 MG Oral Tablet [MEGAVITE WITH FRUITS AND VEGGIES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruits and vegetables (mean 582 g/day) for 12 weeks
Study: 29856132
Drug: Psychotropic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drug intake
Study: 25063905
Drug: OCP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone for 3 months (Group 1)
Study: 25063905
Drug: OCP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone for 3 months (Group 3)
Study: 25063905
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Group 2)
Study: 25063905
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Group 4)
Study: 18372689
Drug: Daily 1
Normalized name: Beauty 360 Daily 1.2% Moisturizing Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 1 hr short radius centrifugation
Study: 12011773
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (300 mg magnesium)
Study: 9787979
Drug: Leukocyte interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte interferon-alpha (1 MU three times weekly for one year)
Study: 9787979
Drug: Leukocyte interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte interferon-alpha (3 MU three times weekly for a second cycle)
Study: 7667053
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg/day iv, divided into 4 daily doses for 4 days)
Study: 2764271
Drug: Theophylline injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline injection, 4 mg/kg body weight
Study: 18641035
Drug: NRTI-sparing regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI-sparing regimen (NNRTI + boosted protease inhibitor)
Study: 16510640
Drug: Urinary antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary antibiotic prophylaxis
Study: 16510640
Drug: No urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No urinary antibiotic prophylaxis (Control)
Study: 15510485
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (MMC) during trabeculectomy
Study: 11022835
Drug: Pinaverlum bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverlum bromide (50 mg, t.i.d.)
Study: 11022835
Drug: Mebeverine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine (100 mg, t.i.d.)
Study: 9486028
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.005% once daily for 4 weeks
Study: 9486028
Drug: latanoprost 0.001%
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.001% once daily for 4 weeks
Study: 3551827
Drug: Praziquantel at
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel at a dose of 75 mg/kg per day
Study: 31526286
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg daily
Study: 31526286
Drug: PUVA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA (3 weekly sessions)
Study: 31591018
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 4 mg
Study: 31591018
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) dexamethasone 4 mg
Study: 25066385
Drug: Xylazine administered
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine administered intravenously (i.v.)
Study: 25066385
Drug: Xylazine administered
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine administered intra-osseously (IO)
Study: 18343265
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) nasal spray (110 microg)
Study: 18343265
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) nasal spray (200 microg)
Study: 27670577
Drug: Short-course antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotics (4 days)
Study: 27670577
Drug: Long-course antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course antibiotics (duration not specified)
Study: 25596054
Drug: Flutamide-combined androgen
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide-combined androgen blockade therapy (F-CAB)
Study: 25596054
Drug: LH-RH monotherapy
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH monotherapy
Study: 22652371
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dl-α-tocopheryl acetate (VE1)
Study: 22652371
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dl-α-tocopheryl acetate (VE2)
Study: 22652371
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dl-α-tocopheryl acetate (VE3)
Study: 20444744
Drug: PRO 2000
Normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO 2000 gel 0.5%
Study: 20444744
Drug: PRO 2000
Normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO 2000 gel 2%
Study: 18517084
Drug: Fluticasone furoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate, 110 microg once daily